Anthem Biosciences (ANTHEM) Q1 25/26 earnings summary

Executive summary

• Q1 FY26 delivered strong year-on-year growth, driven by a ramp-up in CRDMO revenue streams, robust demand for commercialized molecules, and operational excellence.

• Both CRDMO and Specialty Ingredients segments contributed to performance, supported by strategic investments and client partnerships.

• This was the first quarter post-IPO, with shares listed on NSE and BSE on July 21, 2025.

• Unaudited standalone and consolidated financial results for the quarter ended June 30, 2025, were approved by the Board and reviewed by the Audit Committee and statutory auditors.

• Mr. Ravi Kalla was re-designated as Chief Information Officer, effective August 13, 2025.

Financial highlights

• Consolidated revenue for Q1 FY26 was INR 540.21 crore (₹5,402.09 Mn), up 59.5% year-on-year; CRDMO contributed INR 452.7 crore (₹4,527 Mn), Specialty Ingredients INR 87.5 crore (₹875 Mn).

• EBITDA stood at INR 214.3 crore (₹2,143 Mn) with a margin of 38.1%; PAT was INR 135.8 crore (₹1,357.91 Mn), PAT margin at 24.1%.

• Net cash position as of June 30, 2025, was INR 784.8 crore (₹7,848 Mn).

• EPS (consolidated, basic) for Q1 FY26 was Rs. 2.43, up from Rs. 1.48 in Q1 FY25.

• Revenue grew 60% year-on-year, mainly due to higher volumes in commercialized molecules.

Outlook and guidance

• Management expects to maintain historical CAGR of around 20% year-on-year, with Q1 seen as an exceptional quarter due to lumpiness in business.

• EBITDA and gross margins are expected to remain steady, in line with FY 2025 levels.

• Management anticipates continued growth, leveraging expanded capacity and new facilities to support future performance.

• The company completed its IPO and ESOP allotment during the quarter, positioning for future growth.